532977-52-9Relevant articles and documents
CC chemokine receptor-3 (CCR3) antagonists: Improving the selectivity of DPC168 by reducing central ring lipophilicity
Pruitt, James R.,Batt, Douglas G.,Wacker, Dean A.,Bostrom, Lori L.,Booker, Shon K.,McLaughlin, Erin,Houghton, Gregory C.,Varnes, Jeffrey G.,Christ, David D.,Covington, Maryanne,Das, Anuk M.,Davies, Paul,Graden, Danielle,Kariv, Ilona,Orlovsky, Yevgeniya,Stowell, Nicole C.,Vaddi, Krishna G.,Wadman, Eric A.,Welch, Patricia K.,Yeleswaram, Swamy,Solomon, Kimberly A.,Newton, Robert C.,Decicco, Carl P.,Carter, Percy H.,Ko, Soo S.
, p. 2992 - 2997 (2008/02/05)
DPC168, a benzylpiperidine-substituted aryl urea CCR3 antagonist evaluated in clinical trials, was a relatively potent inhibitor of the 2D6 isoform of cytochrome P-450 (CYP2D6). Replacement of the cyclohexyl central ring with saturated heterocycles provid
Asymmetric synthesis of a new helix-forming β-amino acid: trans-4-aminopiperidine-3-carboxylic acid
Schinnerl, Marina,Murray, Justin K.,Langenhan, Joseph M.,Gellman, Samuel H.
, p. 721 - 726 (2007/10/03)
We report a synthesis of a protected derivative of trans-4aminopiperidine-3-carboxylic acid (APiC). The route provides either enantiomer. All intermediates are purified by crystallization, and large-scale preparation is therefore possible. An analogous ro